Article Text

Download PDFPDF
DI-065 Follow up study of HIV patients with boosted protease inhibitor monotherapy in routine clinical practice
  1. J Serra López-Matencio,
  2. M Concepcion,
  3. E Ramirez Herraiz,
  4. D Elisa,
  5. M Alberto
  1. Hospital de La Princesa, Pharmacy, Madrid, Spain


Background Strategies to simplify HIV treatment are driven by concerns about the long-term toxicity of chronic combination antiretroviral therapy (ART), cost, and the risk of drug resistance over time due to non-adherence. Ritonavir-boosted protease inhibitors (PIs) can be an alternative.

Purpose To assess the effectiveness and safety of ritonavir-boosted PI monotherapy and whether the switching has been done in compliance with European AIDS Clinical Society guidelines.

Material and methods A large, retrospective observational, non-interventionist study was carried out including 91 patients on ritonavir-boosted PI monotherapy. Patients were followed since they started ART to December 2013 (the date at which all of the patients had been switched for at least 6 months). Data were collected and summarised in a table with the following characteristics: Date of HIV diagnose, PI/r monotherapy toxicity, Adherence and Date of starting with PI/r monotherapy, viral load at the moment of the simplification, viral load in December 2013.

Results 21 out of 91 (23%) patients had detectable HIV-RNA at the moment of the simplification thus they did not meet the guideline recommendations for switching. 15 out of 91 (16%) patients had a detectable viral load on December 2013 thus the switching had failed in them. Patients had fewer episodes of lipodystrophy, only 14 out of 91 (15%), and cardiovascular complications, only 4 out of 91 (4.35%). 84 out of 91 (92%) patients had more than 85% adherence to the treatment.

Conclusion The overall effectiveness of ritonavir-boosted protease inhibitor monotherapy is inferior to ART. However 84% of patients have no viral rebound with HIV-RNA levels above 50 copies/ml, which is why there may be a subset of patients with a history of prolonged viral suppression who may benefit from switching to ritonavir-boosted protease inhibitor (PI) monotherapy to reduce adverse reactions and costs, and achieve more adherence.

References and/or acknowledgements Hospital de La Princesa Team

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.